Jack Nicklaus Defamation Lawsuit Over LIV Golf Kept in Court
Nicklaus and Milstein have battled each other in New York and Florida courts over the aftermath of a multi-document, $145 million transaction in 2007.
More from Sportico.com
Cristiano Ronaldo Hints $550M Saudi Arabia Tenure Is Over
Wrigley Field Neighbor Slams Cubs for Rowdy, Disruptive Fan Behavior
The Eagles' 'Tush Push' Lives On. Its Trademark Is In Her Hands
At the time, Nicklaus sold the company GBI Investors to Milstein in a deal that gave rise to Nicklaus Companies. GBI Investors had licensed Nicklaus' intellectual property—including his NIL and trademarks—and oversaw his golf course design business. The transaction contained four agreements (purchase and sale; limited liability company or LLC; noncompete; and employment) and each contained forum selections, with New York or Florida listed as the applicable state.
The relationship between Nicklaus and Milstein eventually soured. The two disagreed about business matters, including the extent to which, and under which circumstances, Nicklaus could license his IP to golf tournaments and other projects. In 2022, Nicklaus resigned from Nicklaus Companies' board.
That same year Nicklaus Companies sued GBI Investors and Nicklaus in New York for breach of contract, tortious interference and related claims. In March a judge held that Nicklaus preserved licensing authority for his NIL, including for deals related to golf course design. Nicklaus Companies, however, owns certain trademarks connected to its licensing, golf course design and several brands, including Golden Bear™ and Jack Nicklaus™. New York litigation involving these parties remains on the docket.
In the Florida case, Nicklaus is the plaintiff. He argues the defendants defamed him in statements that 'went viral around the world and tarnished his reputation.' The statements concerned Nicklaus meeting with representatives of Golf Saudi in 2021 for the design of a Jack Nicklaus Signature course in Saudi Arabia. At the time, Saudi Golf was planning LIV Golf and eyed Nicklaus for a leadership role. As Nicklaus tells it, he rebuffed Golf Saudi's overtures because he knew it would prove problematic with the PGA Tour, an organization that is directly connected to his legacy as winner of a record 18 major championships. He also insists Milstein and Nicklaus Companies played no meaningful role in his decision.
Nicklaus argues that Nicklaus Companies defamed him by claiming Milstein and company officials saved him from moving forward with Golf Saudi. Nicklaus also contends that Nicklaus Companies suggested to clients and others that Nicklaus, 85, was exhibiting signs of dementia and 'needed to have his car keys taken away.'
Whether Nicklaus can prove defamation remains to be seen, but a contract-based forum clause defense for Nicklaus Companies won't end the case.
Writing for himself and Judges Dorian K. Damoorgian and Ed Artau, Judge Spencer D. Levine affirmed a trial court's denial of Nicklaus Companies' motion to dismiss based on language in an LLC agreement in 2007. The agreement stated that disputes over 'any action or proceeding arising out of or relating to this agreement' are heard in New York.
Nicklaus Companies asserts that Nicklaus' defamation case is tied to statements and allegations made in the company's lawsuit in New York and are connected to the LLC agreement.
Levine disagreed. He wrote the LLC agreement does not apply to alleged defamation.
'No nexus existed,' the judge explained, 'between the defamation claim and the LLC agreement.'
Levine explained that the LLC agreement concerned such business topics as 'organizational matters; capital, capital accounts, and members; distributions; allocations of net profits and net losses; operations; interests and transfers of interests; and dissolution, liquidation, and termination of the Company as well as buy-out rights.' Those subjects, Levine reasoned, contrast with Nicklaus accusing the defendants of making 'false statements relating to Nickalus and the new Saudi golf league.' The Saudi matter is 'wholly independent from the LLC agreement.'
The Florida case involving Nicklaus will thus continue.
In a statement shared with Sportico, a spokesperson for Nicklaus Companies stressed the appellate court 'did not rule on any issue of fact in favor of one party or another' and instead ruled on where a trial would be held. The spokesperson also mentioned that the Florida court previously 'denied Mr. Nicklaus's motion for punitive damages.'
As Nicklaus Companies tells it, the complaint the company filed in New York 'was never given to any reporter, and the facts show the goal was always to minimize public attention while the rights of the parties were properly determined by the New York court,' and no one at the company defamed Nicklaus.
'We maintain the greatest respect for Mr. Nicklaus's legacy and have always hoped to work with him again in some capacity,' the spokesperson said. 'We still hold that hope. In the meantime, we are confident the jury will agree with our position once all the evidence is presented in court.'
Best of Sportico.com
College Athletes as Employees: Answering 25 Key Questions
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Coloplast A/S – Interim Financial Report, 9M 2024/25
By GlobeNewswire Published on August 19, 2025, 10:33 IST 2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT 1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin 1,2 was 28%, against 27% last year. was DKK 1,915 million, a 2% increase from last year. The EBIT margin was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT 1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin 1 was 27%, on par with last year 2 . was DKK 5,718 million, a 4% increase from last year. The EBIT margin was 27%, on par with last year . Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. 'We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2024/25 conference call For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFO Tel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter MønsterSr. Media Relations ManagerTel. +45 4911 2623 Email: [email protected] Address Coloplast A/SHoltedam 1DK-3050 HumlebaekDenmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_release Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Los Angeles Times
5 hours ago
- Los Angeles Times
Judge's ruling block two players from competing for USC and UCLA this season
When they chose to continue their college careers, both USC offensive lineman DJ Wingfield and UCLA wide receiver Kaedin Robinson thought the courts and NCAA had cleared the way for them to play a fifth season of football. USC had told Wingfield as much, offering him $210,000 in NIL to join the Trojans' offensive line. UCLA, meanwhile, offered Robinson $450,000 to be one of the Bruins' top wideouts. But after first seeing their waivers rejected in the spring, then suing the NCAA this summer, a U.S. District Court judge has now shut the door on either Wingfield or Robinson suiting up this fall. Both players had hoped to prove this week in court that they were deserving of a preliminary injunction that would allow them to play out the season at USC and UCLA. Their attorneys argued that the NCAA's Five-Year Rule, which limits athletes to four seasons in five years, violated antitrust laws by limiting athletes' eligibility — and thus, their NIL earning potential. To block Wingfield and Robinson from playing this season, their attorneys argued, would mean causing 'irreparable harm'. But after a hearing was held for both Monday, a judge in California's Central District court quickly rejected those claims, denying the request for injunctive relief from both players, as well as San Diego linebacker Jagger Giles. Either could appeal the decision, but it's unlikely that either player's case would be heard soon enough to play the 2025 season. Others who have challenged the NCAA's eligibility rules in court have had inconsistent results. But in the case of Wingfield and Robinson, Judge James Selna held that the NCAA's Five-Year Rule was not 'commercial in nature,' but rather a 'true eligibility rule,' and therefore was not beholden to antitrust scrutiny. Not every judge has come to the same conclusion, as a cascade of similar eligibility cases have been filed in the months since Vanderbilt quarterback Diego Pavia won a preliminary injunction in his case against the NCAA. Pavia was granted a fifth season after challenging that the NCAA's rule counting his junior college tenure toward his overall NCAA eligibility would unfairly limit his ability to earn NIL compensation. The judge in Wingfield and Robinson's case was less swayed by that argument. 'There is a subtle difference between a rule that retrains NIL compensation and a rule that limits one's potential to negotiate a NIL agreement,' the judge wrote. 'Putting aside the NIL agreements, the question of whether a player's time has run remains in full force. The eligibility question is not tethered to the question of compensation or commercial transaction.' In Wingfield's case, the judge also found that the five-month delay in Wingfield requesting a temporary restraining order after being ruled ineligible in March weakened the urgency of Wingfield's claims of 'irreparable harm.' Losing Wingfield will undoubtedly deal a significant blow to USC, which had been counting on Wingfield to step into a starting role along the offensive line. Without him, the Trojans will enter the season perilously thin on the interior. Wingfield's collegiate career began in 2019 at El Camino College, a junior college in Torrance. He left El Camino during the 2020 season because of the pandemic, then returned in 2021 before transferring to New Mexico in the spring of 2022. An injury ended his first season with the Lobos before he finished a single game, but he returned to play in nine games in 2023 before transferring to Purdue, where he started along the Boilermakers' line as a fifth-year senior in 2024. Robinson took a very similar path as Wingfield through junior college, spending one season at ASA College in Brooklyn before the pandemic, then redshirted for a season at Central Florida in 2021 before spending the next three years at Appalachian State. Robinson was an All-Sun Belt selection at receiver last season with 53 catches for 840 yards and two touchdowns. He was expected to be one of the Bruins' top receivers this season.
Business Wire
7 hours ago
- Business Wire
Technologent Partners with ITOCHU Techno-Solutions Corporation to Launch StageCrew in North America
IRVINE, Calif.--(BUSINESS WIRE)--StageCrew™ (Stage Crew), a cloud service that streamlines information collection and coordination in system operations and strengthens observability, will be provided in SaaS format by Technologent. This marks the first full-scale deployment in the United States of a Japan-developed cloud service independently created by ITOCHU Techno-Solutions Corporation. 'In Technologent, we have found a partner that not only shares this forward-looking perspective but has the proven capability to guide enterprises on their digital transformation journeys." 'We're thrilled to bring StageCrew to our customers as the North American service provider as part of our commitment to AI enabling our customers,' said Mike McLaughlin, CIO and Sr. Vice President of Professional Services at Technologent. 'By combining Technologent's deep expertise with StageCrew's AI-powered operational intelligence, we're not just solving problems—we're redefining how enterprises manage complexity and stay ahead of disruption.' "Our vision for StageCrew has always been to create an AI-transformed experience that moves IT operations from being reactive to proactive. A vision this ambitious cannot be realized alone,' said Nagaki Fujioka, Managing Executive Officer and COO, Digital Services Group, at ITOCHU Techno-Solutions Corporation. 'In Technologent, we have found a partner that not only shares this forward-looking perspective but has the proven capability to guide enterprises on their digital transformation journeys. Together, ITOCHU Techno-Solutions Corporation and Technologent are not simply selling software; we are building a new operational standard, powered by Multimodal AI and delivered through a partnership committed to tangible, transformative results for every client," continued Fujioka. Market Background In recent years, the need for accurate real-time system monitoring to ensure stable operations has increased significantly. However, using multiple tools for monitoring across many technology services, log collection and cross-discipline assessments has created significant challenges. These include time and labor-intensive coordination between departments and difficulties in aggregation and consolidation of information. This often complicates the identification of issues, root causes as well as establishing corrective action. In North America, the growing complexity of systems, driven by advancements in cloud-native solutions and microservices technologies, has heightened the demand for solutions that improve efficiency, reduce time-to-resolution and decrease manual effort. About StageCrew StageCrew is a cloud-based service developed by ITOCHU Techno-Solutions Corporation designed to enhance visibility and efficiency in system operations. It improves observability (the ability to monitor and understand system health) by integrating with a wide range of monitoring and log collection tools, providing a unified view of critical data across complex IT environments. By consolidating information and standardizing how incidents are handled, StageCrew helps IT teams respond to issues swiftly and consistently, ultimately improving service reliability. StageCrew empowers IT operations with a scalable, AI-enhanced platform that not only streamlines incident management but also promotes a culture of proactive monitoring and continuous improvement. In summary, StageCrew helps organizations run more resilient, observable, and efficient IT systems – ensuring that technology teams can respond faster, work smarter, and deliver more reliable services to the enterprise. Service Implementation Technologent will provide StageCrew in a SaaS model for the North American market delivered from a dedicated cloud infrastructure. Comprehensive support will be provided from pre-implementation consulting to design, PoC (Proof of Concept), and post-implementation support services to meet North American customer needs. Additional service and product engineering support will be provided to Technologent from ITOCHU Techno-Solutions Corporation, Japan. About Technologent Technologent is a women-owned, WBENC-certified and global provider of Information Technology solutions and services for Fortune 1000 companies. With our internationally recognized technical and sales team and well-established partnerships between the most cutting-edge technology brands, Technologent powers your business through a combination of foundational IT disciplines: Data, Security, Cloud and Artificial Intelligence. Together with Service Provider Solutions, Financial Services, Professional Services and our people, we're paving the way for your business operations with advanced problem-solving that isn't just reactive, but forward-thinking and future-proof. Technologent is a trademark of Thomas Gallaway Company, LLC dba Technologent in the United States and other jurisdictions.
